Keratin Bone Graft Matrix for Osteogenic Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

In adult and elderly populations, the multipotency of endogenous stem cells is hindered by changes such as PPARγ2 activation, limiting the effectiveness of regenerative treatments for bone repair due to suppressed osteogenic differentiation and enhanced adipogenic pathways.

Innovation Solution

Malleable bone graft compositions comprising keratose, kerateine, particulate fillers, and mesenchymal or adipose-derived stem cells, with keratose and kerateine in a specific ratio, optionally including BMP2, to promote tissue formation and differentiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If endogenous stem cells are used for bone repair in adult and elderly patients, then the treatment approach is simple and utilizes the patient's own cells, but the multipotency of these cells is hindered by PPARγ2 activation which suppresses osteogenic differentiation

Engineering Contradiction:

Improveease of treatment implementationVSAvoideffectiveness of bone repair

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent introduces an exogenous keratin-based biomaterial as an intermediary carrier that delivers osteoinductive factors (such as BMP-2) to the injury site. This mediator bypasses the limitations of aged endogenous stem cells by providing external osteogenic signals that directly promote bone formation, while the keratin matrix serves as a biocompatible delivery vehicle that supports controlled release of these factors.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the biochemical environment at the injury site by introducing specific osteoinductive factors (BMP-2, TGF-β, PDGF) that change the differentiation parameters of available stem cells. By altering the local concentration and type of growth factors, the system overrides the age-related suppression of osteogenic pathways and promotes bone-specific differentiation even in elderly patients.

Inventive Principle:

Principle #35Parameter changes

2Strength

If traditional bone graft materials are used, then structural support is provided, but they lack the ability to actively promote osteogenic differentiation in aged stem cells

Engineering Contradiction:

Improvestructural supportVSAvoidability to promote tissue differentiation

Core Design Contradiction:

StrengthVSAdaptability or versatility

Solution Approach 1:

The patent creates a composite biomaterial system combining keratin proteins (α-keratin and γ-keratin) with osteoinductive growth factors and potentially other bioactive components. This composite structure provides both the mechanical strength and structural support of the keratin matrix and the biological activity of the embedded growth factors, enabling simultaneous structural reinforcement and active promotion of osteogenic differentiation.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The keratin-based biomaterial performs multiple functions: it provides structural support as a scaffold, serves as a controlled-release delivery system for osteoinductive factors, creates a favorable biochemical environment for stem cell differentiation, and offers biocompatibility and biodegradability. This multi-functionality replaces the need for separate structural and biological components.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If high concentrations of osteoinductive factors are used to overcome PPARγ2 activation, then osteogenic differentiation is enhanced, but the risk of adverse effects and cost increases

Engineering Contradiction:

Improveosteogenic differentiation efficiencyVSAvoidadverse effects and treatment cost

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements continuous controlled-release delivery of osteoinductive factors from the keratin matrix throughout the bone healing process. The biomaterial maintains therapeutic concentrations of growth factors at the injury site over an extended period, ensuring continuous osteogenic stimulation without requiring high initial doses. This sustained release profile improves efficiency while reducing peak concentrations that could cause adverse effects.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent uses high concentrations of osteoinductive factors during the critical early phase of bone healing to rapidly overcome PPARγ2 activation and establish osteogenic differentiation before adipogenic pathways can dominate. This rushing through the critical window of differentiation allows subsequent lower concentrations to maintain the process, reducing overall exposure to high factor levels and associated risks.

Inventive Principle:

Principle #21Skipping (Rushing through)

Data Source

PatentEP2640408B1Keratin compositions for treatment of bone deficiency or injury

Publication Date: 2016.05.25 WAKE FOREST UNIVERSITY HEALTH SCIENCES INC

Figure 1
Figure 2A~2B
Figure 3~4

AI summary

A bone graft composition is described, with one or more of: (a) keratose; (b) kerateine; (c) optionally, particulate filler; (d) optionally, an antibiotic; and (e) water or saline. The composition may be provided in sterile form in a container, and optionally lyophilized. Methods of treating a bone deficiency or fracture making use of such compositions are also described.